Summary
Pharmagrex is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.3m and a net result of €284,105. Equity is growing by about 16% per year across the filed financial years. Its solvency ranks better than 75% of 3,022 sector peers (NACE 64, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
24-02
Gazette deed
Resignation: SEGAL Ivo Marie Paul Mathieu Rita Ghislain (director)Reappointment: BLEYS Martine Maria Jozef (director)5 facts ▸
- Director resignation, SEGAL Ivo Marie Paul Mathieu Rita Ghislain (director)
- Director reappointment, BLEYS Martine Maria Jozef (director)
- Board composition, BLEYS Martine Maria Jozef (director) (2 times)
- Board composition, De Groof Bénédicte (director)
- Board composition, De Groof Alexander (director)
Show earlier events
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.